Obesity Management

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.

Researchers analyzed the association between adherence to a Mediterranean diet and obesity cancers, with a focus on the mediating role adiposity plays throughout the process.

All dosages of semaglutide (Wegovy) under the new program will be available at $499 per month for patients that are uninsured or who do not have coverage for obesity medication.

“The Commission reinforces that obesity is a disease and not due to lack of motivation, willpower, discipline, or laziness,” Robert F. Kushner said.

Researchers determined the prevalence of weight management interventions among patients who were obese and received an obstructive sleep apnea diagnosis.

The announcement comes after the FDA declared the shortage of semaglutide (Ozempic, Wegovy) has been resolved after being in shortage since March 2022.

The results of this study show that the concurrent presence of asthma and obesity did not synergistically amplify inflammation in children with both asthma and overweight/obesity.

Semaglutide has been in shortage since 2022 due to increased demand.

Tirzepatide (Mounjaro, Zepbound), a glucagon-like peptide-1 (GLP-1) medication, demonstrates improved diabetes control and decreases in insulin requirements.

ASC30, an investigational glucagon-like 1-peptide receptor agonist, demonstrates mean weight reductions from baseline of 4.3% and 6.3% for 2 separate cohorts.

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access to drugs that the organization had reviewed for cost effectiveness in 2022.

For weight loss and antihypertensive effects on systolic and diastolic blood pressure, semaglutide also had increased effects.

Recently, there has been concern around glucagon-like peptide-1 receptor agonists and increase the risk of thyroid cancer, with liraglutide having a black box warning label for the disease.

Researchers addressed the factors leading to and the rates of discontinuation and reinitiation of GLP-1 RAs among adults with obesity.

In a phase 1b/2a clinical trial, investigators evaluated the once weekly subcutaneous drug for safety, tolerability, pharmacokinetics, and proof-of-concept.

Taking once-weekly subcutaneous semaglutide does not increase depression symptoms or suicidal ideation in patients with obesity.

In a post hoc secondary analysis of the BP-CATCH trial, researchers explored the best ways of screening children with high blood pressure and managing their care.

Adolescent obesity rates have risen in recent years, and a number of treatment options can be taken to help reduce the risk of a variety of associated medical problems.

To highlight the effectiveness of pediatric obesity treatment, researchers measured its impact on morbidity and mortality in young adulthood.

For adults with obesity but no diabetes diagnosis, researchers searched for the key factors leading to semaglutide initiation.

Researchers wanted to better understand the accuracy of advertising practices behind websites selling compounded GLP-1 RAs.

Sarah Gray, PharmD, GAICD, explored the unique combination of being both a pharmacist and nutritionist.

RGT-075 from Regor Therapeutics demonstrated a statistically significant 5% placebo-adjusted weight loss in adult patients with obesity or overweight.

Sarah Gray, PharmD, GAICD, discussed her experience as a pharmacist who added nutrition counseling to her clinical expertise.

Sarah Gray, PharmD, GAICD, known as the Nutrition Pharmacist, joined Drug Topics to discuss her experience with patients looking to begin healthier lifestyles at the start of a new year.

MET-097i from Metsera demonstrated substantial reductions in mean body weight in patients with obesity or overweight who did not have type 2 diabetes.

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.

US News & World Report nutrition experts detailed the best types of diets for maintaining patient health in 2025.